Gene expression profiling in women with lymph node‒negative breast cancer to select adjuvant chemotherapy
BlueCross BlueShield Association
Record ID 32014001432
English
Authors' objectives:
To examine whether, compared with conventional risk assessment tools or when used in conjunction with conventional risk assessment tools, gene expression profiling improves outcomes for women who decide that recurrence risk is low enough to forgo adjuvant chemotherapy for node-negative, HR-positive, early-stage breast cancer and for women who otherwise may not have received adjuvant chemotherapy.
Authors' recommendations:
http://www.bcbs.com/blueresources/tec/vols/29/29_3.pdf
Details
Project Status:
Completed
Year Published:
2014
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Breast Neoplasms
- Chemotherapy, Adjuvant
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.